March 26, 2018 / 6:50 AM / 9 months ago

BRIEF-RaQualia Pharma says license agreement for novel P2X7 receptor antagonist

March 26(Reuters) - RaQualia Pharma Inc

* Says it and Asahi Kasei Pharma Corp have entered into a license agreement for a novel P2X7 receptor antagonist discovered through a research collaboration between the two companies

Source text in Japanese:goo.gl/TJ8sZH

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below